Archive for July, 2011

CNS Investment Opportunity

An early-stage CNS therapeutic company on whose board I sit is looking for investments in the UK or the United States. They describe their focus as “development of novel CNS assets that span from early development to human clinical trial stages.” If you would like to learn more, please let me know using the contact […]

What is the best approach to enter the biotechnology business

An interesting thread on the topic of educational paths to enter the biotechnology industry has popped up in the Journal of Commercial Biotechnology Linkedin group. Are you intrigued? Do you have any guidance? Hop over and join the discussion. Check out the Journal of Commercial Biotechnology and my Biotechnology Books for more information on the […]

Building Biotechnology in Turkey

The Turkish response to the innovation score I generated for them in the Scientific American Worldview Scorecard was pretty clear. They interpret their low score — 39th out of 48 countries measured — as an indication that they continue to ‘miss the biotech train.’ The primary reasons for Turkey’s low score are: Relatively weak intellectual […]

Drug Patent Expirations in July 2011

Drug Patent Expirations in July 2011 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ALAMAST Santen pemirolast potassium 5,034,230*PED Jul 2, 2011 ANZEMET Sanofi Aventis Us dolasetron mesylate 4,906,755 Jul 2, 2011 ISTODAX Celgene romidepsin 4,977,138 Jul 6, 2011 VISIPAQUE 320 Ge Healthcare iodixanol RE36418 Jul 12, 2011 […]

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: